Acrivon Therapeutics, Inc.

US$1.61As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:ACRVHealthcare
Country USA
PE (Fwd) •••
TSR 4Y CAGR (40.98%)
Div yield —
ROE (64.63%)
Biotechnology
Beta (5Y) 1.98
PE TTM —
TSR TTM (19.10%)
Mkt cap US$68.99M
ROIC (41.67%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$1.69
5.10%
(44.71%)
Hold 2|11|11|11|8
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.02
0.02
0.02
0.02
16.99%
7.27%
(1.47%)
(9.86%)
Revenue$M
3.585
3.479
3.494
3.694
6.06%
4.75%
2.16%
6.28%
Peers (US$68.99M)
Cap (US$)
PE
67.46M
—
Capital
TTM
5Y
10Y
Leveragex
0.654
2.715
2.036
EBIT/Intx
0.527
0.117
0.116
Own earn%
33.02
(67.63)
(69.43)
Sh yield%
32.13
15.31
15.43
Owners
Insiders/Inst%
5.09
66.20
Short interest%
3.69
SBC / revenue%
5.94
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
18
Op margin range%
26–31
$1 testx
—
Incr. ROIC%
1